| 07/01/22 | Delisting of AS "Olainfarm” shares from the Baltic Main list | AQ |
| 06/01/22 | Notification about results of final buy-back of shares | AQ |
| 30/12/21 | Notification about final share buy-back | AQ |
| 28/12/21 | Correction: Regarding results of a share buy-back offer | AQ |
| 28/12/21 | On substantial participation (4) - specified | AQ |
| 1 day | -0.24% |
| Manager | Title | Age | Since |
|---|---|---|---|
Juris Hmelnickis
CEO | Chief Executive Officer | 46 | 01/01/2026 |
Janis Leimanis
DFI | Director of Finance/CFO | 56 | - |
| Chief Tech/Sci/R&D Officer | - | 01/01/2010 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 19/06/2021 | |
Janis Buks
CHM | Chairman | - | 01/09/2022 |
Roberts Tavjevs
BRD | Director/Board Member | - | - |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.24% | -3.46% | - | - | 148M | |
| +0.56% | +2.99% | +16.99% | +75.76% | 49.85B | |
| -1.74% | +3.05% | +56.51% | +109.86% | 36.89B | |
| -0.54% | +3.63% | -6.84% | +24.50% | 12.43B | |
| -0.68% | -0.99% | +12.09% | +74.10% | 11.69B | |
| +2.86% | +0.96% | +31.25% | +132.30% | 9.04B | |
| -1.36% | +2.18% | +48.00% | -5.72% | 7.15B | |
| +0.34% | +0.77% | +13.87% | +32.21% | 6.7B | |
| -3.16% | -0.44% | +1.50% | +174.22% | 6.66B | |
| +0.21% | -3.66% | -34.95% | -1.46% | 5.45B | |
| Average | -0.38% | +2.31% | +15.38% | +68.42% | 16.21B | |
| Weighted average by Cap. | -0.36% | +2.82% | +24.17% | +79.01% |
Employees
2,191
Sector
Pharmaceuticals
